Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

Benoit You,Andrew R Clamp,Adrian Cook,Iain A. McNeish,Olivier Colomban

Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

2021

Benoit You
Andrew R Clamp
Adrian Cook
Iain A. McNeish
Olivier Colomban

5530Background: ICON8 phase III trial did not show improvement in PFS or OS with first-line weekly dose-dense chemotherapy in EOC. This analysis evaluated the impact of tumor intrinsic primary chem...

Keywords:

Internal medicine
epithelial ovarian cancer
first line chemotherapy
Medicine
Chemotherapy
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations